Skip to main content


Fig. 8 | Breast Cancer Research

Fig. 8

From: Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers

Fig. 8

Differential CREB3L1 mRNA expression between normal and tumor tissue for 48 human cancer types. Data obtained from The Cancer Genome Atlas database, with the number of patients in each group indicated on the x-axis: median ± one quartile; *p <0.05; **p <0.01; ***p <0.001; ns not significant. Cancer tissues with CREB3L1 expression higher in tumor (T) than normal (N) (red asterisks) include: BRCA breast carcinoma, PRAD prostate adenocarcinoma, KICH chromophobe renal cell carcinoma, CHOL cholangiocarcinoma, LIHC liver hepatocellular carcinoma, STAD stomach adenocarcinoma, PAAD pancreatic ductal carcinoma. Cancer tissue with CREB3L1 expression lower in tumor than normal (green asterisks) include: LUSC lung squamous cell carcinoma, KIRC clear cell kidney carcinoma, KIRP papillary kidney carcinoma, BLCA bladder urothelial carcinoma, COAD colon adenocarcinoma1, PCPG pheochromocytoma and paraganglioma, READ rectal adenocarcinoma, SKCM cutaneous melanoma, CESC cervical squamous cell carcinoma. Normal and tumor tissues with similar CREB3L1 expression include ESCA esophageal cancer, GBM glioblastoma multiforme, HNSC head and neck squamous cell carcinoma, LUAD lung adenocarcinoma, SARC sarcoma, THCA papillary thyroid carcinoma, THYM thymoma, UCEC uterine corpus endometrial carcinoma

Back to article page